Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 2.62B 2.25B 2.08B 1.95B 3.66B 247B 3.7B 24.53B 9.56B 121B 9.82B 9.61B 420B P/E Ratio 2026 *
-95x
P/E Ratio 2027 * 19.5x
Enterprise Value 2.62B 2.25B 2.08B 1.95B 3.66B 247B 3.7B 24.53B 9.56B 121B 9.82B 9.61B 420B EV / Sales 2026 *
3.76x
EV / Sales 2027 * 2.89x
Free-Float
96.93%
Yield 2026 *
-
Yield 2027 * -
1 day-1.70%
1 week-1.22%
Current month+2.36%
1 month-2.69%
3 months-11.76%
6 months-22.33%
Current year-25.74%
1 week 60.08
Extreme 60.08
64.59
1 month 56
Extreme 56
65.27
Current year 56
Extreme 56
83.92
1 year 38.51
Extreme 38.51
85.25
3 years 12.57
Extreme 12.57
85.25
5 years 10.8
Extreme 10.8001
85.25
10 years 10.8
Extreme 10.8001
85.25
Manager TitleAgeSince
Chief Executive Officer 48 01/09/2018
Director of Finance/CFO 64 24/04/2023
Chief Operating Officer 57 16/07/2020
Director TitleAgeSince
Director/Board Member 72 18/02/2026
Director/Board Member 80 01/01/2017
Director/Board Member 71 19/11/2020
Date Insider Type Main position Quantity % Market Cap.
04-24Fiscal year

Director

2,766 0.0065%
03-20Sell

Chief Operating Officer

2,989 0.0070%
03-17Sell

Chief Technology Officer

1,144 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-1.70%-1.22%+47.25%+228.47% 2.66B
-0.04%-0.24%+17.61%-21.50% 62.57B
-3.55%-4.69%+54.37%+191.44% 57.25B
+0.08%+33.30%+33.30%+33.30% 40.76B
-0.33%+6.43%-55.72%-61.90% 36.28B
-1.53%-1.75%+49.28%-34.24% 29.33B
+6.27%+16.07%+113.08%-56.96% 20.68B
-2.19%-3.37%+40.06%+57.76% 20.37B
-1.29%+4.44%-4.86%+108.17% 17.17B
-1.06%-3.06%+51.02%+95.81% 16.04B
Average -0.54%+3.26%+34.54%+54.04% 30.31B
Weighted average by Cap. -0.72%+2.38%+29.73%+38.68%

Financials

2026 *2027 *
Net sales 696M 600M 553M 519M 974M 65.84B 984M 6.53B 2.54B 32.24B 2.61B 2.56B 112B 905M 780M 718M 674M 1.27B 85.52B 1.28B 8.48B 3.3B 41.88B 3.39B 3.32B 145B
Net income -28.48M -24.54M -22.6M -21.22M -39.84M -2.69B -40.26M -267M -104M -1.32B -107M -105M -4.57B 158M 136M 125M 118M 221M 14.93B 223M 1.48B 577M 7.31B 593M 580M 25.34B
Net Debt - -
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Employees
370
Date Price Change Volume
16/06/26 60.80 $ -1.70% 718,791
15/06/26 61.85 $ -0.16% 502,415
12/06/26 61.95 $ -1.05% 267,322
11/06/26 62.61 $ +2.19% 399,703
10/06/26 61.27 $ -0.45% 319,938
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
60.80USD
Average target price
94.11USD
Spread / Average Target
+54.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!